GlassScriptPhysician profile
Brandi Holt
NPI 1790405967
$2,241.66
in general payments reported to CMS, 2019-2025
18 companies · $1,700 in 2025
The $1,700 reported for 2025 was more than what 90% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $64.82 · 2023: $388 · 2024: $89.41 · 2025: $1,700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,159 · Education: $18.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,158.66 |
| Education | $18.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $838.33 | 2025 | Auvelity, Symbravo |
| Abbvie INC. | $286.81 | 2023-2025 | |
| Collegium Pharmaceutical, INC. | $197.16 | 2022-2025 | Belbuca, Jornay Pm |
| Janssen Pharmaceuticals, INC | $164.66 | 2025 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $130.33 | 2022-2023 | Relistor |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $115.39 | 2024-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $92.24 | 2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $85.70 | 2025 | Rexulti |
| Tris Pharma INC | $60.80 | 2025 | Dyanavel Xr, Onyda Xr |
| Lundbeck LLC | $49.96 | 2023-2025 | Rexulti, Vyepti |
| Takeda Pharmaceuticals U.S.A., INC. | $44.89 | 2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $43.71 | 2025 | Qelbree |
| Alkermes, INC. | $39.99 | 2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $29.54 | 2025 | |
| Scilex Pharmaceuticals INC. | $21.25 | 2023 | Ztlido |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $17.27 | 2025 | Austedo Xr |
| Fidia Pharma USA INC. | $14.14 | 2023 | Triluron, Hymovis |
| Corium, LLC | $9.49 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandi Holt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.